NEW YORK, NY / ACCESSWIRE / February 22, 2022 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
First Solar, Inc. (NASDAQ:FSLR)
CONTACT JAKUBOWITZ ABOUT FSLR:
https://claimyourloss.com/securities/first-solar-inc-loss-submission-form/?id=23941&from=1
This lawsuit is on behalf of all persons or entities that purchased or otherwise acquired shares of First Solar common stock between February 22, 2019, and February 20, 2020, inclusive.
Lead Plaintiff Deadline : March 8, 2022
According to the filed complaint, defendants made repeated misrepresentations to investors regarding the development of First Solar’s newest “Series 6” solar module, the cost per unit it could achieve with that module, and the impact the changeover to this new product would have on the viability of its other business segments. As a result of defendants’ misrepresentations, First Solar common stock traded at artificially inflated prices during the class period.
Standard Lithium Ltd. (NYSE:SLI)
CONTACT JAKUBOWITZ ABOUT SLI:
https://claimyourloss.com/securities/standard-lithium-ltd-loss-submission-form/?id=23941&from=1
Class Period : May 19, 2020 – November 17, 2021
Lead Plaintiff Deadline : March 28, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the LiSTR Direct Lithium Extraction technology’s extraction recovery efficiencies were overstated; (ii) accordingly, the Company’s final product lithium recovery percentage at the Demonstration Plant would not be as high as the Company had represented to investors; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
CONTACT JAKUBOWITZ ABOUT FENC:
https://claimyourloss.com/securities/fennec-pharmaceuticals-inc-loss-submission-form-2/?id=23941&from=1
Class Period : May 28, 2021 – November 26, 2021
Lead Plaintiff Deadline : April 11, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application (“NDA”); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE : Jakubowitz Law
View source version on accesswire.com:
https://www.accesswire.com/689877/LAWSUITS-FILED-AGAINST-FSLR-SLI-and-FENC–JAKUBOWITZ-LAW-PURSUES-SHAREHOLDERS-CLAIMS
